These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820 [TBL] [Abstract][Full Text] [Related]
10. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B. Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro. Iwashita S; Shoji T; Koizumi M Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789 [TBL] [Abstract][Full Text] [Related]
12. A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics. Elkhashab M; Dilek Y; Foss M; Creemers LB; Howard KA Mol Pharm; 2024 Feb; 21(2):491-500. PubMed ID: 38214218 [TBL] [Abstract][Full Text] [Related]
13. Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides. Yoshida T; Morihiro K; Naito Y; Mikami A; Kasahara Y; Inoue T; Obika S Nucleic Acids Res; 2022 Jul; 50(13):7224-7234. PubMed ID: 35801870 [TBL] [Abstract][Full Text] [Related]
14. Site-specific incorporation of 5'-methyl DNA enhances the therapeutic profile of gapmer ASOs. Vasquez G; Freestone GC; Wan WB; Low A; De Hoyos CL; Yu J; Prakash TP; Ǿstergaard ME; Liang XH; Crooke ST; Swayze EE; Migawa MT; Seth PP Nucleic Acids Res; 2021 Feb; 49(4):1828-1839. PubMed ID: 33544849 [TBL] [Abstract][Full Text] [Related]
15. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Migawa MT; Shen W; Wan WB; Vasquez G; Oestergaard ME; Low A; De Hoyos CL; Gupta R; Murray S; Tanowitz M; Bell M; Nichols JG; Gaus H; Liang XH; Swayze EE; Crooke ST; Seth PP Nucleic Acids Res; 2019 Jun; 47(11):5465-5479. PubMed ID: 31034558 [TBL] [Abstract][Full Text] [Related]
16. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093 [TBL] [Abstract][Full Text] [Related]
17. RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides. Hori SI; Mitsuoka Y; Kugimiya A Nucleic Acid Ther; 2019 Feb; 29(1):44-50. PubMed ID: 30508397 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells. Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease. Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341 [TBL] [Abstract][Full Text] [Related]
20. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity. Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]